Logo image of PACB

PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Fundamental Analysis

NASDAQ:PACB - Nasdaq - US69404D1081 - Common Stock - Currency: USD

1.31  +0.01 (+0.77%)

After market: 1.3 -0.01 (-0.76%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PACB. PACB was compared to 55 industry peers in the Life Sciences Tools & Services industry. PACB may be in some trouble as it scores bad on both profitability and health. PACB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PACB has reported negative net income.
In the past year PACB has reported a negative cash flow from operations.
In the past 5 years PACB reported 4 times negative net income.
PACB had negative operating cash flow in 4 of the past 5 years.
PACB Yearly Net Income VS EBIT VS OCF VS FCFPACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

PACB has a Return On Assets of -76.41%. This is amonst the worse of the industry: PACB underperforms 89.09% of its industry peers.
Looking at the Return On Equity, with a value of -717.77%, PACB is doing worse than 90.91% of the companies in the same industry.
Industry RankSector Rank
ROA -76.41%
ROE -717.77%
ROIC N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
PACB Yearly ROA, ROE, ROICPACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

PACB's Gross Margin of 19.49% is on the low side compared to the rest of the industry. PACB is outperformed by 83.64% of its industry peers.
In the last couple of years the Gross Margin of PACB has declined.
PACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
PACB Yearly Profit, Operating, Gross MarginsPACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PACB has more shares outstanding
PACB has more shares outstanding than it did 5 years ago.
PACB has a worse debt/assets ratio than last year.
PACB Yearly Shares OutstandingPACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PACB Yearly Total Debt VS Total AssetsPACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

PACB has an Altman-Z score of -5.44. This is a bad value and indicates that PACB is not financially healthy and even has some risk of bankruptcy.
PACB has a worse Altman-Z score (-5.44) than 90.91% of its industry peers.
A Debt/Equity ratio of 7.05 is on the high side and indicates that PACB has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 7.05, PACB is doing worse than 92.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 7.05
Debt/FCF N/A
Altman-Z -5.44
ROIC/WACCN/A
WACC6.41%
PACB Yearly LT Debt VS Equity VS FCFPACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 6.68 indicates that PACB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.68, PACB belongs to the top of the industry, outperforming 85.45% of the companies in the same industry.
PACB has a Quick Ratio of 5.87. This indicates that PACB is financially healthy and has no problem in meeting its short term obligations.
PACB has a Quick ratio of 5.87. This is amongst the best in the industry. PACB outperforms 87.27% of its industry peers.
Industry RankSector Rank
Current Ratio 6.68
Quick Ratio 5.87
PACB Yearly Current Assets VS Current LiabilitesPACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

PACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -144.74%.
The Revenue for PACB has decreased by -23.98% in the past year. This is quite bad
Measured over the past years, PACB shows a quite strong growth in Revenue. The Revenue has been growing by 11.12% on average per year.
EPS 1Y (TTM)-144.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-396.55%
Revenue 1Y (TTM)-23.98%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-4.27%

3.2 Future

Based on estimates for the next years, PACB will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.33% on average per year.
Based on estimates for the next years, PACB will show a quite strong growth in Revenue. The Revenue will grow by 13.89% on average per year.
EPS Next Y50.35%
EPS Next 2Y28.5%
EPS Next 3Y20.8%
EPS Next 5Y12.33%
Revenue Next Year1.41%
Revenue Next 2Y9.64%
Revenue Next 3Y13.69%
Revenue Next 5Y13.89%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PACB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PACB Price Earnings VS Forward Price EarningsPACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PACB Per share dataPACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PACB's earnings are expected to grow with 20.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.5%
EPS Next 3Y20.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PACB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (6/18/2025, 8:17:29 PM)

After market: 1.3 -0.01 (-0.76%)

1.31

+0.01 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners65.88%
Inst Owner Change-13.86%
Ins Owners0.99%
Ins Owner Change18.02%
Market Cap393.10M
Analysts75.24
Price Target1.98 (51.15%)
Short Float %19.08%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-390.43%
Min EPS beat(2)-646.96%
Max EPS beat(2)-133.89%
EPS beat(4)1
Avg EPS beat(4)-236.67%
Min EPS beat(4)-646.96%
Max EPS beat(4)3.93%
EPS beat(8)3
Avg EPS beat(8)-114.97%
EPS beat(12)4
Avg EPS beat(12)-76.99%
EPS beat(16)5
Avg EPS beat(16)-59.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-4.25%
Max Revenue beat(2)3.35%
Revenue beat(4)1
Avg Revenue beat(4)-5.28%
Min Revenue beat(4)-13.63%
Max Revenue beat(4)3.35%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)7
Avg Revenue beat(16)-0.25%
PT rev (1m)-7.72%
PT rev (3m)-23.51%
EPS NQ rev (1m)4.33%
EPS NQ rev (3m)7.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.11%
Revenue NQ rev (1m)-0.32%
Revenue NQ rev (3m)-3.46%
Revenue NY rev (1m)-0.63%
Revenue NY rev (3m)-2.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.58
P/FCF N/A
P/OCF N/A
P/B 4.29
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.51
BVpS0.31
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.41%
ROE -717.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.49%
FCFM N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 7.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.16%
Cap/Sales 5.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.68
Quick Ratio 5.87
Altman-Z -5.44
F-Score2
WACC6.41%
ROIC/WACCN/A
Cap/Depr(3y)74.27%
Cap/Depr(5y)63.44%
Cap/Sales(3y)7.21%
Cap/Sales(5y)5.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-144.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-396.55%
EPS Next Y50.35%
EPS Next 2Y28.5%
EPS Next 3Y20.8%
EPS Next 5Y12.33%
Revenue 1Y (TTM)-23.98%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-4.27%
Revenue Next Year1.41%
Revenue Next 2Y9.64%
Revenue Next 3Y13.69%
Revenue Next 5Y13.89%
EBIT growth 1Y-89.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.97%
EBIT Next 3Y20.98%
EBIT Next 5Y17.19%
FCF growth 1Y38.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.45%
OCF growth 3YN/A
OCF growth 5YN/A